Company news
Contact us
- Suzhou hisiyuan Instrument Equipment Co., Ltd
- Contact person: Manager Peng
- phone：180-1314-3418
- Company seat：0512-67158275
- mailbox：hsy_001@hsy515.cn
- Address:Unit 101, building 14, Max Science Park, No. 998, pangnan Road, Jiangling street, Wujiang District, Suzhou
Company news
Your current location:Home / News / Company newsLeading China's new drugs, enabling innovation and development
Article source:Leading China's new drugs, enabling innovation and development Hits:729 Release time:2020-04-30
Invitation letter
In the surging "fast follow" tide, where will Chinese medicine go in the future?
There is no alternative to explore new drugs that can truly meet clinical needs and realize market value, and accelerate their listing in China and even the world.
A new set of solutions is needed to meet this huge challenge. The key to success is to have a good understanding of clinical needs, to master the advanced technologies of global biomedicine, to keep up with the constantly updated drug administration and regulations, and to reengineer and optimize the new drug R & D process.
Lead new drugs in China, enabling innovation and development. The first "Global Conference on frontier technologies, policies and regulations of biomedicine" (main forum + seven sub forums) will be held in Suzhou from October 30 to November 1. Numerous reports and round table discussions directly hit the pain points of China's pharmaceutical industry
Who can become "Huawei pharmaceutical"?
Is the time to be an original drug?
How to stand out from homogeneous R & D?
What will be the next blockbuster after PD-1?
How to deal with the crisis caused by the scarcity of targets?
Antibody drug innovation: what can we do in the future?
For solid tumors, how to break through cell therapy?
How to develop MAH for R & D institutions?
In October, the 70th anniversary of the motherland, tongfreehand ushered in the 15th anniversary of the birthday. As a grand commemorative activity, we warmly invite you to participate in this conference, and jointly write about the next decade of new drugs in China with top scientists, regulatory experts and clinical experts in the world.
Sponsor丨freehand new drug talent Club
Co organizers丨drug R & D innovation Working Committee of China Pharmaceutical Enterprise Management Association, BioBAY, biosatellite gene Biotechnology Co., Ltd
The guiding unit 丨 are the central biotechnology and pharmaceutical Working Committee of the Chinese agricultural and industrial Democratic Party, the China Pharmaceutical Enterprise Management Association, and the Suzhou Industrial Park Management Committee
Organizer丨 tongshuyi (Beijing) science and Technology Development Co., Ltd
Main forum
schedule
09:00-18:00, October 30
Executive Chairman: Zhu Xun and Yu Dechao
Policy orientation of new drug innovation in China
Guest speaker
Opportunities and challenges of biopharmaceutical development in China
Professor Gao Fu: academician of Chinese Academy of Sciences and director of China Center for Disease Control and Prevention
Biotechnology development in the United States: innovation and breakthrough
Dr.William J. Rutter: academician of American Academy of Sciences, HCV discoverer and chairman of synergetics LLC
Development of antitumor drugs based on innate immunity
Guest speaker
Policy orientation of speeding up drug evaluation and approval
Dr. Xu Zengjun: chief scientist of drug evaluation center of State Drug Administration
Who can become China's "Huawei pharmaceutical"?
Professor Li Jin: Director of Oncology Department of Shanghai Oriental Hospital and President of China Society of Clinical Oncology (CSCO)
30 years of agitation (2005-2035) -- Review and prospect and analysis of the future development path of Chinese Pharmaceutical Enterprises
Professor Zhu Xun: Chairman of tongfreehand new drug talent Club
Frontier technology and development trend of Biopharmaceutics
Dr. Yu Dechao: Chairman of Xinda biology
Clinical drug demand and drug innovation of nervous system diseases
Professor Wang Yongjun: executive vice president of Beijing Tiantan Hospital
Unmet clinical drug demand and drug development for liver diseases
Professor Niu Junqi: Vice President of Institute of translational medicine, the first hospital of Jilin University
Translational medicine of lung cancer and its latest development
Professor Zhou caicun: Chairman of CSCO Special Committee on non-small cell lung cancer, director of Institute of cancer, School of medicine, Tongji University
Antibody and car-t drug innovation, what can we do
Dr. Liu Cheng: founder and CEO of eureko
Independent innovation and breakthrough of original biological drugs
Dr. Fang Jianmin: CEO and chief scientist of Rongchang biopharmaceutical
SHP2 and KRAS channels, next wave of heavy bombs after PD-1
Dr. Wang Yinxiang: Chairman of Beijing jiakesi
Good science makes new drug research and development win the strong with the weak
Dr. Xie Yuli: general manager and executive director of Suzhou Unilink
Desire driven industry and pharmaceutical legal environment in the United States
Meng Bayi: special FDA commentator
Round table forum: how to breakthrough new drugs in China in the next decade (to invite guests)
Du Ying: Chairman of zaiding pharmaceutical
Zhang Lianshan: Vice President of Hengrui pharmaceutical
Wu Xiaobin: general manager and President of Baiji Shenzhou
He Ruyi: chief scientist of innovative medical health of SDIC
Lu Xianping: CEO of microchip
Li Ning: executive director and general manager of Junshi biology
Jiang Ningjun: CEO of cornerstone pharmaceutical
Yang Dajun: Chairman of Yasheng pharmaceutical
Chen Li: Chairman of Hualing pharmaceutical
15th Anniversary Party of tongfreehand and award ceremony of Chinese medical innovation figures (directional invitation)
Parallel topic sub Forum
09:00-18:00, October 31
08:30-12:30, November 01
The content of the sub forum will be released in succession in the near future, please look forward to it.
Forum 1 Antibody drug discovery and Innovation: what can we do in the future
International frontier, new target and new technology platform of antibody research and development
[chairman] Lu Hongtao (co founder and CSO of Kewang pharmaceutical)
[Planning] Chen Mingjiu (founder and CEO of BOCOM)
Wang Jun (researcher, New York University, USA)
LV Zhijian (former head of Novartis China biopharmaceutical research and innovation department)
Forum 2 Industrialization development of new antibody: bispecific antibody and beyond
Antibody engineering, quality control, clinical trials, industrialization technology and policies and regulations
[chairman] Zhu Zhenping (President and CSO, Sansheng pharmaceutical R & D)
[Planning] Shen Wenyan (Senior Vice President, NGM biopharmaceuticals)
Gu Jijie (CSO and executive vice president of YaoMing Biology)
Forum 3 Cellular immunotherapy: a new era of drug intervention
Car-t cells and innovation of gene therapy drugs
[chairman] Liu Cheng (founder of eureko biology, USA)
[Planning] Xu Zhongwei (Chairman of beicelt Biology)
Zhang Yu (CEO of Yiang Biology)
Forum 4 Stand out from homogeneous R & D: innovative drug project and clinical R & D
Project evaluation, target review, translational medicine, clinical research and development, AI and drug discovery
[chairman] Lu Xianping (CEO of microchip)
[Planning] Li Jing (founder of Yaodu)
Xie Yuli (general manager of the company)
Wang Zaiqi (founder of Yingshi Biology)
Peng bin (CMO of Anmai Biology)
Zou Jianjun (vice president of Hengrui pharmaceutical)
Du Tao (chief consultant of HPC)
Li Xing (founder of deep Zhiyao)
Forum 5 Breakthrough of key points in the development of chemical pharmacy and the practice of MAH in R & D institutions
Pharmaceutical research of raw materials and preparations, clinical sample production and MAH practice
[chairman] Wu Zhenping (Senior Vice President of Hutchison Whampoa pharmaceutical)
Guo Ming (co founder of Yasheng medicine)
Forum 6 The road of improved drug innovation
[chairman] Zhao Xiaobin (founder of the whiteoak group)
Tong Weiqin, President of Aosida pharmaceutical
[Planning] Wen Hong (CSO of Lizhu group)
Wang Qingsong (CEO of Nanjing Qingpu Biology)
Forum 7 Opportunities and risks of biomedical investment
[chairman] Wu Qinggong (vice president of China Pharmaceutical Enterprise Management Association, director of investment and financing Working Committee, director of H50)
Hong Tan (managing director of Junlian capital)
[Planning] Tan Yong (chief editor of E medicine manager and Secretary General of H50)
Supply chain Salon Sustainable development of enterprises in complex international environment
Media support
Finance and economics, medical circles, people's network, arterial network, Sina medicine, e-medicine manager, cypress blue, minenet, dandelion, siqiquan, BioBAY, immune time, China Medical Journal, medical economic news, China Cancer Foundation China Cancer Yearbook, Chinese Journal of clinical and rehabilitation of cancer, electronic journal of comprehensive treatment of tumor, Journal of clinical hepatobiliary disease, R & D customer, biological exploration, Kai Si club, yimaike, biopharmaceutical editor, pharmaceutical affairs vertical and horizontal, yaozhiwang, insight database, converging Nanyao, YanRuYu, zhizhiya, huihuiyaojia, HPC Yaowen pharmaceutical, qianyuanhui, chemical processing, preferred capital, Lanting capital
‘
WeChat scan